Lung-MAP Trial Expands to Include All NSCLC Patients

Dave Levitan writing for Cancer Network reports that the Lung-MAP (Lung Cancer Master Protocol) trial is expanding to patients with all non-small-cell lung cancers (NSCLC). This covers 85% of all lung cancer diagnoses in the United States. Initiated in 2014, Lung-MAP has registered more than 1,800 patients at more than 600 centers around the nation. Once patients are enrolled, they undergo comprehensive genomic profiling—those who qualify are matched to a specific therapy being tested on various genetic parameters. Meg Mooney, MD, MBA with the National Cancer Institute’s Cancer Therapy Evaluation Program notes that the trial has already “proven its value by successfully completing trials with new targeted agents in selected, molecularly defined subsets of squamous cell lung cancer.” More recently, the leaders of the trial published a review touting the design’s success. “Cumulative experience from this overarching, multi-institution master protocol has demonstrated centralized, real-time biomarker screening is feasible and sub-study modularity is essential for protocol adaptability in a rapidly changing treatment landscape,” wrote Vincent K. Lam, MD, and Vassiliki Papadimitrakopoulou, MD, both of the University of Texas MD Anderson Cancer Center in Houston. Papadimitrakopoulou is the lead investigator for the Lung-MAP trial.

Lead Research/Investigator

Meg Mooney, MD, MBA